Physician profile
Peter Joseph Smith
NPI 1710152962
$1,806.26
in general payments reported to CMS, 2019-2025
16 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $246 · 2023: $499 · 2024: $498 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $665.57 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $422.03 | 2021-2025 | |
| Novo Nordisk INC | $177.52 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $136.47 | 2022-2024 | Quviviq |
| Glaxosmithkline, LLC. | $102.36 | 2021-2025 | Trelegy Ellipta |
| Inspire Medical Systems, INC. | $57.98 | 2024 | Inspire |
| Abbott Laboratories | $40.46 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $38.94 | 2023 | |
| Lilly USA, LLC | $37.84 | 2022-2024 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $32.66 | 2025 | |
| Amgen INC. | $21.03 | 2024 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $19.46 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.35 | 2023 | Trintellix |
| Antares Pharma, INC. | $15.20 | 2021 | |
| Sanofi Pasteur INC. | $14.89 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $5.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.